Related Experiment Video
Updated: Apr 12, 2026

A Protocol for Explant Cultures of IDH1-mutant Diffuse Low-grade Gliomas
Published on: May 9, 2025
Mutant IDH1: An immunotherapeutic target in tumors
Theresa Schumacher1, Lukas Bunse1, Wolfgang Wick2
1DKTK Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology; German Cancer Research Center ; Heidelberg, Germany ; Department of Neurooncology; University Hospital Heidelberg ; Heidelberg, Germany.
Abstract:
The discovery of driver mutations in cancers has raised interest in their suitability as immunotherapeutic targets. A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a mutation-specific CD4+ antitumor T cell response in patients and a syngeneic tumor model in MHC-humanized mice.
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Abnormal Proliferation

